After a hypersensitivity reaction to ferric maltose presenting with dizziness, infusion‑site pain, and toe pain that has been stabilized, should the patient be transferred to the emergency department from the infusion clinic?

Management Decision: No ER Transfer Required for Stabilized Mild-to-Moderate Reaction

After a stabilized reaction to ferric maltose presenting with dizziness, local infusion-site pain, and toe pain (likely arthralgias), the patient does NOT require transfer to the emergency department and can be safely discharged from the infusion clinic with appropriate counseling and follow-up instructions. 1

Clinical Reasoning

Reaction Classification

The symptoms described—dizziness, local pain, and toe pain—are consistent with a mild-to-moderate infusion reaction, most likely representing complement activation-related pseudo-allergy (CARPA) rather than true IgE-mediated anaphylaxis 1. Critically, this patient lacks features of severe/life-threatening hypersensitivity:

• No systemic hypotension (SBP drop ≥30 mmHg or SBP ≤90 mmHg)
• No airway compromise, wheezing, or respiratory stridor
• No angioedema or periorbital edema
• No loss of consciousness
• No gastrointestinal symptoms suggesting anaphylaxis 1

The toe pain specifically suggests arthralgias, which is a characteristic feature of CARPA reactions and can occur with IV iron formulations 1.

Disposition Criteria

According to 2024 expert consensus guidelines, mild and moderate infusion reactions are self-limiting and resolve spontaneously 1. The key decision point is whether symptoms have stabilized:

• If symptoms have resolved or stabilized: Continue monitoring in the infusion clinic until complete resolution, then discharge with counseling 1
• If symptoms worsen after 15 minutes or fail to improve: Consider additional symptom-directed treatment (corticosteroids, antihistamines) but still manage in the infusion clinic setting 1
• Only transfer to ER if: Signs of anaphylaxis develop (hypotension, airway compromise, loss of consciousness) 1

Post-Stabilization Management Protocol

Immediate actions in the infusion clinic:

• Continue monitoring vital signs until patient returns to baseline 1
• Ensure symptoms have completely resolved before discharge 1
• No physiological basis exists for 30-minute post-infusion observation once symptoms have resolved, despite package insert recommendations 1

Patient education before discharge:

• Inform about possible delayed infusion reactions occurring hours to days later 1
• Common delayed symptoms include flu-like symptoms, arthralgias, myalgias, and fever lasting up to 24 hours 1
• These are easily managed with NSAIDs 1
• Symptoms lasting more than a few days require provider evaluation (may indicate hypophosphatemia or other pathology) 1

Important Caveats

The dizziness warrants specific attention: While second-generation antihistamines can cause dizziness, flushing, and palpitations 1, ensure this symptom has fully resolved before discharge. The FDA label notes that transient elevations in blood pressure with dizziness can occur with ferric maltose (Injectafer) and typically resolve within 30 minutes 2.

Consider hypophosphatemia: Toe pain and bone pain can be manifestations of treatment-emergent hypophosphatemia, particularly with ferric carboxymaltose (though less common with ferric maltose/derisomaltose) 1, 2. If symptoms persist beyond 24-48 hours, check serum phosphate levels 2.

Future Iron Administration

If this patient requires additional IV iron:

• Consider premedication (though controversial, limited to high-risk patients) 1
• Consider alternative formulation 1
• Slower infusion rate (50% of initial rate) if rechallenge attempted 1
• Document this reaction thoroughly for future reference

Bottom line: A stabilized mild-to-moderate reaction without features of anaphylaxis does not constitute a medical emergency requiring ER transfer. The infusion clinic is the appropriate setting for completion of monitoring and discharge with proper counseling.